WO2002060866A2 - Preparation of pure 3-alkoxymethyl cephalosporins. - Google Patents

Preparation of pure 3-alkoxymethyl cephalosporins. Download PDF

Info

Publication number
WO2002060866A2
WO2002060866A2 PCT/IB2002/000264 IB0200264W WO02060866A2 WO 2002060866 A2 WO2002060866 A2 WO 2002060866A2 IB 0200264 W IB0200264 W IB 0200264W WO 02060866 A2 WO02060866 A2 WO 02060866A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
aca
acid
molar ratio
reaction
Prior art date
Application number
PCT/IB2002/000264
Other languages
French (fr)
Other versions
WO2002060866A3 (en
Inventor
Yatendra Kumar
Mohan Prasad
Ashok Prasad
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to AU2002226616A priority Critical patent/AU2002226616A1/en
Publication of WO2002060866A2 publication Critical patent/WO2002060866A2/en
Publication of WO2002060866A3 publication Critical patent/WO2002060866A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Definitions

  • the present invention relates to an improved and industrially advantageous process for the preparation of pure 7-amino-3-alkoxymethyl-3-cephem-4- carboxylic acids, and salts thereof.
  • the present invention relates to a process for the preparation of pure 7-amino-3-methoxymethyl-3-cephem- 4-carboxylic acid (7-AMCA) and salts thereof.
  • R is an alkyl group, and salts thereof, are known in the prior art and are important intermediates in the preparation of various cephaiosporin derivatives having a very high and broad spectrum of antimicrobial activity.
  • 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid (7-AMCA) of Formula II 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid (7-AMCA) of Formula II
  • cefpodoxime proxetil an orally active third generation cephaiosporin antibiotic.
  • Pharmaceutical compounds are required in highly pure form because of the fear of unknown and potentially harmful effects of impurities.
  • the purity of intermediates and raw materials is essential for obtaining the target pharmaceutical compounds in high yield and purity.
  • Japanese patent application 57/192392 describes the reaction of 7-ACA with lower alcohols in the presence of an iodine compound to obtain the 7-amino- 3-alkoxymethyl-3-cephem-4-carboxylic acids.
  • Japanese patent application 59/163387 proposes the use of a lower alcohol in the presence of a sulfonic acid.
  • European patent, EP 204657 describes the conversion of 7-ACA to 7- amino-3-alkoxymethyl-3-cephem-4-carboxylic acids using lower alkyl alcohols in the presence of boron trifluoride or a complex thereof, in 60% yield.
  • Japanese patent application 63/115887 describes a variant which involves the additional use of halogenosulfonic acids or alkylsulfonic acids.
  • Japanese patent application 61/45175 achieves the reaction with lower alcohol, an organic sulfonic acid and an alkoxysilane.
  • EP 262744 reports the same conversion using lower alcohols in the presence of a halide of antimony, tin, iron, zinc, bismuth or a complex thereof and optionally boron trifluoride or a complex thereof. The yields are in the range of 40-65% only.
  • EP 343926 describes the reaction of 7-ACA with a protonic acid or a lewis acid, or a borate complex thereof, and an ortho-organic acid ester or acetal to obtain the 7-amino-3-alkoxymethyl-3-cephem-4-carboxylic acids.
  • U.S. Patent No. 5,451 ,675 also provides a process for the production of the 7-amino-3- alkoxymethyl-3-cephem-4-carboxylic acids, comprising reacting 7-ACA with a solution of alkoxysulfonic acid in a lower alcohol in the presence of a trialkyl borate and/or formaldehyde dialkylacetal.
  • the products obtained by these methods were found to have an appreciable amount of an impurity
  • R is an alkyl group having from 1-6 carbon atoms along with lactones of Formula B.
  • Another object of the present invention is to provide a process which makes use of commercially available non-hazardous alkylsulphonic acids and avoids the use of alkoxysulfonic acids which are in turn prepared from chlorosulfonic acids, which are difficult to handle at large scale because of environmental hazards involved.
  • the present invention provides an improved process for the
  • each of said compounds of Formulae I, RSO 3 H, B(OR) 3, CH 2 (OR) _ and ROH, R is an alkyl group having from 1 to 6 carbon atoms.
  • the compounds of Formulae I and III may be in the salt form and include salts at the carboxyl group or the amino group.
  • Representative example of salts at the carboxyl group include salts with an alkali metal, such as sodium and potassium; an alkaline earth metal, such as calcium and magnesium; ammonium salts and salts with nitrogen containing organic bases, such as triethylarnine, pyridine and dicyclohexylamine.
  • salts at the amino group include salts with inorganic acids, such as hydrochloric acid and sulfuric acids; carboxylic acids, such as formic acid, oxalic acid and trifluoroacetic acid; and sulfonic acids, such as methanesulfonic acid or p-toluenesulfonic acid.
  • inorganic acids such as hydrochloric acid and sulfuric acids
  • carboxylic acids such as formic acid, oxalic acid and trifluoroacetic acid
  • sulfonic acids such as methanesulfonic acid or p-toluenesulfonic acid.
  • the compound of formula RS0 3 H is an alkylsulfonic acid wherein R is an alkyl group having from I to 6 carbon atoms.
  • R represents an alkyl group having from 1 to 4 carbon atoms.
  • alkylsulfonic acids include methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, isopropanesulfonic acid, butanesulfonic acid, isobutanesulfonic acid, sec- butanesulfonic acid, t-butanesulfonic acid and hexylsulfonic acid.
  • Preferred alkylsulfonic acids are methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid and butanesulfonic acid, the most preferred being methanesulfonic acid.
  • the process of the present invention is characterized by using at least one compound selected from the compounds of formula B(OR) 3 and the compounds of formula CH 2 (OR) 2 .
  • the compound of formula B(OR) 3 is a trialkyl borate wherein R represents an alkyl group having from 1 to 6 carbon atoms. Preferably, R represent an alkyl group having from 1 to 4 carbon atoms.
  • borates include trimethyl borate, triethyl borate, tripropyl borate, triisopropyl borate, tributyl borate, triisobutyl borate, tri-sec- butylborate, tri-t-butylborate and trihexyl borate.
  • Preferred trialkyl borates are trimethyl borate, triethyl borate, tripropyl borate and tributyl borate. Most preferred is trimethyl borate.
  • the compound of formula CH 2 (OR) 2 is a formaldehyde dialkyl acetal wherein R represents an alkyl group having from 1 to 6 carbon atom. Preferably, R represent an alkyl group having from 1 to 4 carbon atoms.
  • Examples of formaldehyde dialkyl acetal include methylal, ethylal, formaldehyde dipropyl acetal, formaldehyde diisopropyl acetal, formaldehyde dibutyl acetal, formaldehyde di-sec-butyl acetal, formaldehyde di-t-butyl acetal and formaldehyde dihexyl acetal.
  • Preferred are methylal, ethylal, formaldehyde dipropyl acetal and formaldehyde dibutyl acetal. Most preferred is methylal.
  • the compound of formula ROH is a lower alcohol, wherein R is an alkyl group having from 1 to 6 carbon atoms.
  • R represents an alkyl group having from 1 to 4 carbon atoms.
  • examples of such alcohols include methanol, ethanol, propanol, isopropanol, butanol, isobutanol, sec-butanol, t- butanol and hexanol. More preferably, methanol, ethanol, propanol and butanol are used. Most preferred being methanol. It was found that the lower alcohols ROH had a crucial role to play in the selective formation of desired compounds of Formula I and the exclusion of the intermolecular esterification product of Formula A.
  • the molar ratio of lower alcohol ROH used with respect to the starting material 7-ACA of Formula III may be at least 0.1 : 1 so as to minimize the formation of impurities of Formula A. On the other hand, the molar ratio should not exceed 30:1 to obtain best results.
  • the molar ratio of alkyl alcohol to 7-ACA is thus suitably 0.1 :1 to 30:1 and preferably 1 :1 to 10:1.
  • the molar ratio of trialkyl borate of formula B(OR) 3 to the starting material 7- ACA is generally in the range 0.3:1 to 30:1 and preferably from 1 :1 to 10:1.
  • the alkylsulfonic acid RS0 3 H required for the reaction to proceed at a reasonable rate is at least an amount equimolar to the amount of the 7-ACA.
  • the process of the present invention is optionally carried out in the presence of an organic solvent which may include sulfolane, dimethyl sulfoxide, carbonic acid esters, organic acid esters, ethers, nitriles, alkanes, nitroalkanes, halogenated alkanes, cycloalkanes, carboxylic acids, ketones, or mixtures thereof.
  • the solvent is preferably sulfolane, dimethyl carbonate, dichloromethane, dimethyl sulfoxide or a mixture thereof.
  • the reaction is best performed in substantially anhydrous conditions.
  • the moisture content of solvents and reagents is therefore kept at a minimum.
  • reaction temperature is critical. Very low temperatures such as below -20 e C lead to a very sluggish reaction whereas, temperature above 20 C leads to increased formation of impurities of Formula A, as well as formation
  • reaction is generally performed
  • the desired product of Formula I or a pharmaceutically acceptable salt thereof is obtained from the reaction mixture by simple conventional method. Water is added to the reaction mixture and the resultant boric acid is filtered. A water miscible solvent like acetone, methanol or ethanol is added to the filtrate and the pH adjusted to the isoelectric point of the desired product, using aqueous ammonia solution. The resultant precipitate is filtered and washed suitably.
  • the compound of Formula I thus obtained can, if desired, be converted to its salt form by conventional procedures known in the art.
  • the invention is further illustrated by the following examples and comparative examples, which should not be construed to be limiting the scope of the present invention.
  • the obtained precipitate was filtered and washed with water followed by methanol.
  • the product 7-AMCA was dried at room temperature till constant weight (2.8g, yield 62%, HPLC purity 80.1%).
  • the content of the lactone and the ester impurity in the isolated product was 0.2% and 6.22%, respectively (by HPLC).

Abstract

The present invention relates to an improved and industrially advantageous process for the preparation of pure 7-amino-3-alkoxymethyl-3-cephem-4-carboxylic acids, and salts thereof. In particular, the present invention relates to a process for the preparation of pure 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid (7-AMCA) and salts thereof.

Description

PROCESS FOR THE PREPARATION OF PURE 3-ALKOXYMETHYL CEPHALOSPORINS
FIELD OF THE INVENTION
The present invention relates to an improved and industrially advantageous process for the preparation of pure 7-amino-3-alkoxymethyl-3-cephem-4- carboxylic acids, and salts thereof. In particular, the present invention relates to a process for the preparation of pure 7-amino-3-methoxymethyl-3-cephem- 4-carboxylic acid (7-AMCA) and salts thereof.
BACKGROUND OF THE INVENTION
7-amino-3-alkoxymethyl-3-cephem-4-carboxylic acids, i.e. compounds of Formula I
Figure imgf000002_0001
FORMULA I
wherein R is an alkyl group, and salts thereof, are known in the prior art and are important intermediates in the preparation of various cephaiosporin derivatives having a very high and broad spectrum of antimicrobial activity. In particular, 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid (7-AMCA) of Formula II
Figure imgf000003_0001
FORMULA II
is a key intermediate in the preparation of cefpodoxime proxetil, an orally active third generation cephaiosporin antibiotic.
Pharmaceutical compounds are required in highly pure form because of the fear of unknown and potentially harmful effects of impurities. For purposes of patient safety, it is highly desirable to limit the amount of impurities present in any medicament administered to a patient. This is achieved by either devising a process for their preparation in pure form or by additional purification steps like chromatography or recrystallization etc. The former is obviously preferred, as it saves costs as well as time. The purity of intermediates and raw materials is essential for obtaining the target pharmaceutical compounds in high yield and purity.
Several processes are known for the preparation of 7-amino-3-aIkoxymethyl- 3-cephem-4-carboxylic acid, starting from 7-aminocephalosporanic acid (7- ACA).
Japanese patent application 57/192392 describes the reaction of 7-ACA with lower alcohols in the presence of an iodine compound to obtain the 7-amino- 3-alkoxymethyl-3-cephem-4-carboxylic acids. Japanese patent application 59/163387 proposes the use of a lower alcohol in the presence of a sulfonic acid. European patent, EP 204657 describes the conversion of 7-ACA to 7- amino-3-alkoxymethyl-3-cephem-4-carboxylic acids using lower alkyl alcohols in the presence of boron trifluoride or a complex thereof, in 60% yield. Japanese patent application 63/115887 describes a variant which involves the additional use of halogenosulfonic acids or alkylsulfonic acids. Japanese patent application 61/45175 achieves the reaction with lower alcohol, an organic sulfonic acid and an alkoxysilane. EP 262744 reports the same conversion using lower alcohols in the presence of a halide of antimony, tin, iron, zinc, bismuth or a complex thereof and optionally boron trifluoride or a complex thereof. The yields are in the range of 40-65% only.
EP 343926 describes the reaction of 7-ACA with a protonic acid or a lewis acid, or a borate complex thereof, and an ortho-organic acid ester or acetal to obtain the 7-amino-3-alkoxymethyl-3-cephem-4-carboxylic acids. U.S. Patent No. 5,451 ,675 also provides a process for the production of the 7-amino-3- alkoxymethyl-3-cephem-4-carboxylic acids, comprising reacting 7-ACA with a solution of alkoxysulfonic acid in a lower alcohol in the presence of a trialkyl borate and/or formaldehyde dialkylacetal. However, the products obtained by these methods were found to have an appreciable amount of an impurity,
which was hitherto assumed to be a lactone or the β-lactam degradation
compounds. A detailed analysis of the undesirable by-products by Liquid Chromatography-Mass Spectrometry has revealed that the major impurity formed using the above procedures is the inter-molecular esterification product of Formula A,
Figure imgf000005_0001
FORMULA A
where R is an alkyl group having from 1-6 carbon atoms along with lactones of Formula B.
Figure imgf000005_0002
FORMULA B
However, all the above mentioned processes suffer from certain limitations and for various reasons are not suitable for commercial production - for example, low yields, use of hazardous or costly reagents or excessive side product formation. A major reason for the low yields and purity is reported to be the formation of undesirable by-products of Formulae A and B due to
intramolecular lactonization or decomposition of the β-lactam ring. SUMMARY OF THE INVENTION
It is an objective of the present invention to provide a clean reaction resulting in pure products which are obtained by simple isolation procedures involving a single precipitation step, as against the use of column chromatography or successive precipitation steps required in the prior art processes.
Another object of the present invention is to provide a process which makes use of commercially available non-hazardous alkylsulphonic acids and avoids the use of alkoxysulfonic acids which are in turn prepared from chlorosulfonic acids, which are difficult to handle at large scale because of environmental hazards involved.
The present invention solves the problems associated with the prior art and provides a process for the preparation of compounds of Formula I
Figure imgf000006_0001
FORMULA I which minimizes the formation of the by product of Formula A,
Figure imgf000006_0002
FORMULA A thus yielding pure product, using conditions which are convenient to operate
on a commercial scale and operationally safe.
Accordingly, the present invention provides an improved process for the
preparation of 3-alkoxymethy-3-cephem-4-carboxylic acid of Formula I,
Figure imgf000007_0001
FORMULA I
or a salt thereof in pure form, which process comprises reacting 7-
aminocephalosporanic acid (7-ACA) of Formula III,
Figure imgf000007_0002
FORMULA III
or a salt thereof, with an alkylsulfonic acid of formula RSO3H and a trialkylborate of formula B(OR)3 or a formaldehyde dialkyl acetal of formula
CH2(OR) 2 in the presence of a lower alcohol of formula ROH; wherein, in
each of said compounds of Formulae I, RSO3H, B(OR) 3, CH2(OR) _ and ROH, R is an alkyl group having from 1 to 6 carbon atoms. DETAILED DESCRIPTION OF THE INVENTION
The compounds of Formulae I and III may be in the salt form and include salts at the carboxyl group or the amino group. Representative example of salts at the carboxyl group include salts with an alkali metal, such as sodium and potassium; an alkaline earth metal, such as calcium and magnesium; ammonium salts and salts with nitrogen containing organic bases, such as triethylarnine, pyridine and dicyclohexylamine. Examples of salts at the amino group include salts with inorganic acids, such as hydrochloric acid and sulfuric acids; carboxylic acids, such as formic acid, oxalic acid and trifluoroacetic acid; and sulfonic acids, such as methanesulfonic acid or p-toluenesulfonic acid.
The compound of formula RS03H is an alkylsulfonic acid wherein R is an alkyl group having from I to 6 carbon atoms. Preferably, R represents an alkyl group having from 1 to 4 carbon atoms. Examples of such alkylsulfonic acids include methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, isopropanesulfonic acid, butanesulfonic acid, isobutanesulfonic acid, sec- butanesulfonic acid, t-butanesulfonic acid and hexylsulfonic acid. Preferred alkylsulfonic acids are methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid and butanesulfonic acid, the most preferred being methanesulfonic acid.
The process of the present invention is characterized by using at least one compound selected from the compounds of formula B(OR)3 and the compounds of formula CH2(OR)2. The compound of formula B(OR)3 is a trialkyl borate wherein R represents an alkyl group having from 1 to 6 carbon atoms. Preferably, R represent an alkyl group having from 1 to 4 carbon atoms. Examples of such borates include trimethyl borate, triethyl borate, tripropyl borate, triisopropyl borate, tributyl borate, triisobutyl borate, tri-sec- butylborate, tri-t-butylborate and trihexyl borate. Preferred trialkyl borates are trimethyl borate, triethyl borate, tripropyl borate and tributyl borate. Most preferred is trimethyl borate.
The compound of formula CH2(OR)2 is a formaldehyde dialkyl acetal wherein R represents an alkyl group having from 1 to 6 carbon atom. Preferably, R represent an alkyl group having from 1 to 4 carbon atoms. Examples of formaldehyde dialkyl acetal include methylal, ethylal, formaldehyde dipropyl acetal, formaldehyde diisopropyl acetal, formaldehyde dibutyl acetal, formaldehyde di-sec-butyl acetal, formaldehyde di-t-butyl acetal and formaldehyde dihexyl acetal. Preferred are methylal, ethylal, formaldehyde dipropyl acetal and formaldehyde dibutyl acetal. Most preferred is methylal.
The compound of formula ROH is a lower alcohol, wherein R is an alkyl group having from 1 to 6 carbon atoms. Preferably, R represents an alkyl group having from 1 to 4 carbon atoms. Examples of such alcohols include methanol, ethanol, propanol, isopropanol, butanol, isobutanol, sec-butanol, t- butanol and hexanol. More preferably, methanol, ethanol, propanol and butanol are used. Most preferred being methanol. It was found that the lower alcohols ROH had a crucial role to play in the selective formation of desired compounds of Formula I and the exclusion of the intermolecular esterification product of Formula A. The molar ratio of lower alcohol ROH used with respect to the starting material 7-ACA of Formula III may be at least 0.1 : 1 so as to minimize the formation of impurities of Formula A. On the other hand, the molar ratio should not exceed 30:1 to obtain best results. The molar ratio of alkyl alcohol to 7-ACA is thus suitably 0.1 :1 to 30:1 and preferably 1 :1 to 10:1.
The molar ratio of trialkyl borate of formula B(OR)3 to the starting material 7- ACA is generally in the range 0.3:1 to 30:1 and preferably from 1 :1 to 10:1.
The molar ratio of formaldehyde dialkylacetal of formula CH2(OR)2 to 7-ACA is
0.5 : 1 to 30:1 and preferably 1 :1 to 10:1.
The alkylsulfonic acid RS03H required for the reaction to proceed at a reasonable rate is at least an amount equimolar to the amount of the 7-ACA.
Increasing the molar ratio of alkylsulfonic acid to 7-ACA increases the rate of the reaction. However, excess of alkylsulfonic acid leads to increased by- product formation and the molar ratio generally used is 1 :1 to 30:1 and preferably 10:1 to 20:1.
The process of the present invention is optionally carried out in the presence of an organic solvent which may include sulfolane, dimethyl sulfoxide, carbonic acid esters, organic acid esters, ethers, nitriles, alkanes, nitroalkanes, halogenated alkanes, cycloalkanes, carboxylic acids, ketones, or mixtures thereof. The solvent is preferably sulfolane, dimethyl carbonate, dichloromethane, dimethyl sulfoxide or a mixture thereof.
The reaction is best performed in substantially anhydrous conditions. The moisture content of solvents and reagents is therefore kept at a minimum.
The reaction temperature is critical. Very low temperatures such as below -20eC lead to a very sluggish reaction whereas, temperature above 20 C leads to increased formation of impurities of Formula A, as well as formation
of β-lactam degradation products. Thus, the reaction is generally performed
at about -20 to 20SC, and preferably at about -10 to 5SC.
The desired product of Formula I or a pharmaceutically acceptable salt thereof, is obtained from the reaction mixture by simple conventional method. Water is added to the reaction mixture and the resultant boric acid is filtered. A water miscible solvent like acetone, methanol or ethanol is added to the filtrate and the pH adjusted to the isoelectric point of the desired product, using aqueous ammonia solution. The resultant precipitate is filtered and washed suitably. The compound of Formula I thus obtained can, if desired, be converted to its salt form by conventional procedures known in the art.
The invention is further illustrated by the following examples and comparative examples, which should not be construed to be limiting the scope of the present invention. The content of the lactone (Formula B) and the intermolecular esterification impurity (Formula A, when R=CHs) in the desired product are shown as an index for the evaluation of the purity of the desired product.
Preparation of 7-amino-3-met oxymethyl-3-cephem-4-carboxylic acid
EXAMPLE 1
A mixture of methanesulfonic acid (26.5g), sulfolane (15ml) and trimethylborate (13.4g) was cooled to -5QC. 7-ACA (5g) was added to the mixture followed by addition of methanol (2.5ml). Reaction mixture was stirred at 0QC for about 12 hours. Progress of the reaction was monitored by high performance liquid chromatography (HPLC). Reaction was quenched by addition of water (35ml) at 0-5eC. The resultant boric acid precipitate was filtered and washed successively with water and acetone. The filtrate was washed with dichloromethane. The acetone washing was then combined with the aqueous portion. The pH of the aqueous portion was adjusted to 3.4 - 3.5 with an aqueous ammonia solution. The precipitate, so obtained was filtered and washed with water followed by methanol. The product was dried under vacuum at ambient temperature till constant weight to get 3.7g of the desired product 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid (Yield 83%, HPLC purity 95%). The content of the lactone (Formula B), and the ester impurity (Formula A, when R=CH3) in the desired product was 0.27% and 0.70%, respectively (by HPLC). EXAMPLE 2
A mixture of methanesulfonic acid(27.5g), sulfolane (6ml) and trimethylborate (6g) was cooled to -5QC. To this mixture, was added 7-ACA (5g) followed by methanol (2ml). The reaction and its work up were carried out as in Example 1 to obtain 7-AMCA (3.9g, Yield 87%, HPLC purity 95.4%). The content of the lactone and the ester impurity in the product was 0.1% and 1.7%, respectively (by HPLC).
EXAMPLE 3 A mixture of methansulfonic acid (27g) and dichloromethane (30ml) was cooled to -5 C and trimethylborate (6g), 7-ACA (5g) were added to it followed by additional of methanol (2.5ml). The reaction mixture was stirred at 0SC and monitored by HPLC. Reaction was quenched after 10 hours by addition of water (50ml) at 0-5QC. Adjusted pH to 0.5 with ammonia solution. The resultant layers were separated. The pH of the aqueous layer was adjusted to 3.5 using aqueous ammonia solution to get a precipitate which was filtered and washed with water followed by methanol. The product was dried under vacuum to obtain 7-AMCA (3.1 g, Yield 70%, HPLC purity 95.3%). The content of the lactone and the ester impurity in the product was 0.17% and 1.7%, respectively (by HPLC).
EXAMPLE 4
Methanesulfonic acid (22g) and sulfolane (10ml) were cooled to -59C. To this mixture was added methylal (5g) followed by 7-ACA (5g) and methanol (1.25ml). The reaction was carried out at 0QC, monitored by HPLC and quenched after 10 hours by addition of water (80ml) at 0-5QC. The product 7- AMCA (2.75g) was obtained by adjusting pH to 3.5, filtering the resultant precipitate which was washed and dried as in Example 1 (Yield 62%, HPLC purity 94.5%). 0.18% of lactone and 1.9% of ester impurity were present in the isolated product (by HPLC).
COMPARATIVE EXAMPLE 1
A methanolic solution of methoxysulfonic acid (31 g), sulfolane (15ml) and trimethylborate (13.34g) were cooled to -59C. 7-ACA (5g) was added and the reaction mixture stirred at 10-1 ΩC. Progress of reaction was monitored by HPLC and reaction quenched after V/z h by cooling to -10QC, followed by addition of water (40ml). 10% ammonia solution (20ml) was then added. The resulting solution was subjected to activated carbon treatment and then washed with dichloromethane. To the aqueous portion was added methanol and pH was adjusted to 3.4-3.5 with ammonia solution at 15-20QC. The obtained precipitate was filtered and washed with water followed by methanol. The product 7-AMCA was dried at room temperature till constant weight (2.8g, yield 62%, HPLC purity 80.1%). The content of the lactone and the ester impurity in the isolated product was 0.2% and 6.22%, respectively (by HPLC).
COMPARATIVE EXAMPLE 2
To dichloromethane (40ml) were added methanesulfonic acid (20g) and trimethylborate (12.5g). The mixture was cooled to -5SC and 7-ACA (5g) was added. Reaction was carried out and worked up as in Example 3 to obtain 7- AMCA (2.25g, Yield 50%, HPLC purity 82%). 0.28% of lactone and 5.7% of the ester impurity were detected in the isolated product (by HPLC)
COMPARATIVE EXAMPLE 3
Methanesulfonic acid (20g) and sulfolane (10ml) were cooled to -10 to -12QC and 7-ACA(5g) was added to it followed by trimethylborate (11.25g) maintaining temperature at -5 to -29C. Reaction was stirred at 09C and monitored by HPLC. Reaction was worked up as in Example 1 to obtain 7- AMCA (3.2g, Yield 72% HPLC purity : 85.5%). 0.17% of lactone and 6% of ester impurity were found in the isolated product, (by HPLC).
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Claims

WE CLAIM :
1. A process for the preparation of 3~alkoxymethyl-3-cephem-4- carboxylic acid of Formula I
Figure imgf000016_0001
FORMULA I
or a salt thereof, which process comprises reacting 7- aminocephalosporanic (7-ACA) of Formula III,
Figure imgf000016_0002
FORMULA πi
or a salt thereof, with an alkylsulfonic acid of formula RS03H and a trialkylborate of formula B(OR)3 or a formaldehyde dialkyl acetal of formula CH2(OR)2 in the presence of a lower alcohol of formula ROH; wherein, in each of said compounds of Formulae I, RSO3H and B(OR)3, (CH2(OR)2,and ROH, R represents an alkyl group having from 1 to 6 carbon atoms.
2. The process of claim 1 wherein R represents an alkyl group having from 1 to 4 carbon atoms.
3. The process of claim 2 wherein R represents a methyl, ethyl, propyl or butyl group.
4. The process of claim 3 wherein R represents a methyl group.
5. The process of claim 1 wherein R represents the same group in said compounds of Formulae I, RS03H, ROH, CH2(OR)2 and B(OR)3.
6. The process of claim 1 wherein the molar ratio of alkylsulfonic acid of Formula RS03H to 7-ACA is from 1 :1 to 30:1.
7. The process of claim 6 wherein the molar ratio of alkylsulfonic acid of Formula RS03H to 7-ACA is from 10:1 to 20:1.
8. The process of claim 1 wherein the molar ratio of borate compound of formula B(OR)3 to 7-ACA is from 0.3:1 to 30:1.
9. The process of claim 8 wherein the molar ratio of borate compound of formula B(OR)3 to 7-ACA is from 1 :1 to 10:1.
10. The process of claim 1 wherein the molar ratio of formaldehyde dialkyl acetal of Formula CH2(OR)2 to 7-ACA is from 0.5:1 to 30:1.
11. The process of claim 10 wherein the molar ratio of formaldehyde dialkyl acetal of Formula CH2(OR)2 to 7-ACA is from 1 :1 to 10:1.
12. The process of claim 1 wherein the molar ratio of lower alcohol of Formula ROH to 7-ACA is from 0.1 :1 to 30:1.
13. The process of claim 12 wherein the molar ratio of lower alcohol of Formula ROH to 7-ACA is from 1 :1 to 10:1.
14. The process of claim 1 wherein the reaction is carried out in an anhydrous or substantially anhydrous system.
15. The process of claim 1 wherein the reaction is carried out at a temperature of from about -20SC to 20SC.
16. The process of claim 15 wherein the reaction is carried out at a temperature of from about -10 to 5QC.
17. The process of claim 1 wherein the reaction is carried out in the presence of an organic solvent.
18. The process of claim 17 wherein the reaction is carried out in the presence of an organic solvent selected from a group consisting of sulfolane, dimethyl sulfoxide, carbonic acid esters, organic acid esters, ethers, nitriles, alkanes, nitroalkanes, halogenated alkanes, cycloalkanes, carboxylic acids, ketones, and mixtures thereof. A process for the preparation of 3-methoxymethyl-3-cephem-4- carboxylic acid (7-AMCA) of Formula II,
Figure imgf000019_0001
FORMULA II
or a salt thereof, which process comprises reacting 7- aminocephalosporanic acid (7-ACA) of Formula III
Figure imgf000019_0002
FORMULA III
with methanesulfonic acid and trimethylborate or methylal in the presence of methanol.
PCT/IB2002/000264 2001-01-30 2002-01-29 Preparation of pure 3-alkoxymethyl cephalosporins. WO2002060866A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002226616A AU2002226616A1 (en) 2001-01-30 2002-01-29 Preparation of pure 3-alkoxymethyl cephalosporins.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN71DE2001 IN192344B (en) 2001-01-30 2001-01-30
IN071/DEL/2001 2001-01-30

Publications (2)

Publication Number Publication Date
WO2002060866A2 true WO2002060866A2 (en) 2002-08-08
WO2002060866A3 WO2002060866A3 (en) 2006-04-13

Family

ID=11097024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/000264 WO2002060866A2 (en) 2001-01-30 2002-01-29 Preparation of pure 3-alkoxymethyl cephalosporins.

Country Status (3)

Country Link
AU (1) AU2002226616A1 (en)
IN (1) IN192344B (en)
WO (1) WO2002060866A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108530468A (en) * 2018-03-21 2018-09-14 山东睿鹰先锋制药有限公司 A kind of Cefpodoxime Proxetil impurity and its preparation method and application
CN112480144A (en) * 2020-12-07 2021-03-12 湖北凌晟药业有限公司 Preparation method of 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451675A (en) * 1990-11-07 1995-09-19 Sankyo Company, Limited Process for the preparatuon of 3-alkoxymethyl cephalosporin derivatives
WO2001027117A1 (en) * 1999-10-13 2001-04-19 Hanmi Pharm. Co., Ltd. Process for preparing 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451675A (en) * 1990-11-07 1995-09-19 Sankyo Company, Limited Process for the preparatuon of 3-alkoxymethyl cephalosporin derivatives
WO2001027117A1 (en) * 1999-10-13 2001-04-19 Hanmi Pharm. Co., Ltd. Process for preparing 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108530468A (en) * 2018-03-21 2018-09-14 山东睿鹰先锋制药有限公司 A kind of Cefpodoxime Proxetil impurity and its preparation method and application
CN112480144A (en) * 2020-12-07 2021-03-12 湖北凌晟药业有限公司 Preparation method of 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid

Also Published As

Publication number Publication date
AU2002226616A1 (en) 2002-08-12
WO2002060866A3 (en) 2006-04-13
AU2002226616A8 (en) 2006-11-02
IN192344B (en) 2004-04-10

Similar Documents

Publication Publication Date Title
CN112358427B (en) Synthetic method of trifluoro-methyl-thionate compound
CN111757868B (en) Nitric oxide donating prostaglandin analogs
KR20130090472A (en) Novel salts of difluoromethylthioacetic acid, the preparation method thereof and the preparation method of (7r)-benzhydril-(2-(difluoromethylthio)acetamino)-3-(chloromethyl)-7-methoxy-8-oxo-5-oxa-1-aza-bicyclo[4.2.0]oct-2-ene-carboxylate using said salts as intermediate meterial
US6639068B1 (en) Method of preparing highly pure cefpodoxime proxetil
US5093532A (en) Process for the preparation of halogenomethylketones, in particular of 1,1,1-trifluoroacetone
WO2002060866A2 (en) Preparation of pure 3-alkoxymethyl cephalosporins.
US6620930B1 (en) Process for preparing 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid
Toya et al. Improved Synthetic Methods of Firefly Luciferin Derivatives for Use in Bioluminescent Analysis of Hydrolytic Enzymes; Carboxylic Esterase and Alkaline Phosphatase.
KR100342600B1 (en) New Thiazole compounds and their preparations
US20040210050A1 (en) Process for the preparation of highly pure cefuroxime axetil
JP2612493B2 (en) Method for producing 3-substituted methyl-3-cephem-4-carboxylic acids
KR100401284B1 (en) Method for preparing 1-bromoethyl acetate
CN109232609B (en) Method for preparing high-purity cefpodoxime proxetil
KR100477763B1 (en) The Novel preparation of Intermediate of Cefatrizine Propylene gylcol
US6207841B1 (en) Bisphenol derivative and its manufacturing method
CA2036208A1 (en) Process for the preparation of 7-amino-3-methoxymethylceph-3-em-4-carboxylic acid
EP0024824B1 (en) Process for the production of alpha-halogeno-beta-amino propionitriles or of mineral acid salts thereof
KR101106517B1 (en) Method for producing piperidin-4-one derivative
Dao et al. Synthesis of 8-methyl-2-O-methyl-3, 5-O-(1-methyl ethylidene)-6, 7, 8, 9-tetradeoxy-D-gulo-6-nonenonic acid (6E)--lactone
KR20030067764A (en) Method for preparing cephalosporin compound
EP1165582A2 (en) Novel method for the production of etoposide
KR19990002112A (en) Penem derivatives and preparation method thereof
KR20050110103A (en) Novel process for producing cefonicid intermediate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP